Search

Your search keyword '"Poupart, Marc"' showing total 243 results

Search Constraints

Start Over You searched for: Author "Poupart, Marc" Remove constraint Author: "Poupart, Marc"
243 results on '"Poupart, Marc"'

Search Results

3. Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.

4. Comparison between exclusive (chemo)radiation and surgery or induction chemotherapy as first curative treatment for localized or locally advanced head and neck squamous cell carcinomas (L(A)-HNSCC): Sub-analysis of the EPOCKS study

5. Addictions, Social Deprivation and Cessation Failure in Head and Neck Squamous Cell Carcinoma Survivors

7. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study

8. sj-docx-1-tmj-10.1177_03008916221078061 – Supplemental material for Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study

9. Allosteric N-acetamide-indole-6-carboxylic acid thumb pocket 1 inhibitors of hepatitis C virus NS5B polymerase--acylsulfonamides and acylsulfamides as carboxylic acid replacements

10. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study

15. Proof of Concept of a Binary Blood Assay for Predicting Radiosensitivity

17. Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease

18. Phosphorylation of the cohesin subunit Scc1 by Polo/Cdc5 kinase regulates sister chromatid separation in yeast

19. Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast

20. Stereoselective synthesis of renin inhibitor BILA 2157 BS

22. Solid-phase synthesis of peptidyl trifluoromethyl ketones

23. Design and Synthesis of Macrocyclic Inhibitors of the Hepatitis C NS3 Protease

24. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

25. A convergent enantioselective approach involving new arrangements for the actuation of ring D cyclization

26. Expedient construction of the tetracyclic core by oxyanionic sigmatropy

29. Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule

31. Management of unilateral head and neck carcinoma of unknown primary: Retrospective analysis of the impact of postoperative radiotherapy target volumes.

34. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

35. Neoadjuvant TP (Cisplatin-Docetaxel) for patients unfit to TPF (Cisplatin-Docetaxel-5FU) in locally advanced head and neck squamous cell cancer (LAHNSCC): an exploratory study on 14 patients

36. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma&nbsp

37. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma 

38. Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor

41. N-Acetamideindolecarboxylic acid allosteric ‘finger-loop’ inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies

42. Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection

43. A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy

44. Discovery of the First Thumb Pocket 1 NS5B Polymerase Inhibitor (BILB 1941) with Demonstrated Antiviral Activity in Patients Chronically Infected with Genotype 1 Hepatitis C Virus (HCV)

46. Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor

48. Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast

49. Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1

Catalog

Books, media, physical & digital resources